Journal of the European Academy of Dermatology and Venereology
With the increasing number of options for the treatment of moderate‐to‐severe atopic dermatitis, ... more With the increasing number of options for the treatment of moderate‐to‐severe atopic dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent for specific patient populations. We convened an expert panel consisting of 12 members to conduct a literature review and summarize relevant data related to six scenarios of clinical interest: comorbid asthma, ocular surface disease, history of cancer, past and ongoing infections of interest (including herpes simplex virus, herpes zoster, hepatitis B, and tuberculosis), pregnancy and lactation, and the elderly. We performed a literature search and examined each clinical scenario with respect to three major categories of available systemic agents: traditional systemics (azathioprine, cyclosporine A, methotrexate, and mycophenolate mofetil), Janus kinase inhibitors (abrocitinib, baricitinib, and upadacitinib), and biologics (dupilumab, lebrikizumab, and tralokinumab). The expert panel and steering committee met ...
TNF antagonists revolutionized the treatment of several high-needs inflammatory conditions includ... more TNF antagonists revolutionized the treatment of several high-needs inflammatory conditions including plaque psoriasis and hidradenitis suppurativa. After an initial, sputtering start in MS, septic shock, and congestive heart failure, clinical trials in rheumatoid arthritis established a development path in chronic inflammatory diseases. Plaque psoriasis was a serendipitous passenger on the psoriatic arthritis train. Over many years of development, dozens of clinical trials, and thousands of patients in registries, we know TNF to be a central cytokine mediating many chronic inflammatory diseases. We also know that therapeutic blockade of TNF is remarkably safe. Yet to be established are collateral benefits of treatment with TNF antagonists.
Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psor... more Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psoriasis in randomized clinical trials.
Journal of the European Academy of Dermatology and Venereology
With the increasing number of options for the treatment of moderate‐to‐severe atopic dermatitis, ... more With the increasing number of options for the treatment of moderate‐to‐severe atopic dermatitis, clinicians need guidance on a practical approach to selecting a systemic agent for specific patient populations. We convened an expert panel consisting of 12 members to conduct a literature review and summarize relevant data related to six scenarios of clinical interest: comorbid asthma, ocular surface disease, history of cancer, past and ongoing infections of interest (including herpes simplex virus, herpes zoster, hepatitis B, and tuberculosis), pregnancy and lactation, and the elderly. We performed a literature search and examined each clinical scenario with respect to three major categories of available systemic agents: traditional systemics (azathioprine, cyclosporine A, methotrexate, and mycophenolate mofetil), Janus kinase inhibitors (abrocitinib, baricitinib, and upadacitinib), and biologics (dupilumab, lebrikizumab, and tralokinumab). The expert panel and steering committee met ...
TNF antagonists revolutionized the treatment of several high-needs inflammatory conditions includ... more TNF antagonists revolutionized the treatment of several high-needs inflammatory conditions including plaque psoriasis and hidradenitis suppurativa. After an initial, sputtering start in MS, septic shock, and congestive heart failure, clinical trials in rheumatoid arthritis established a development path in chronic inflammatory diseases. Plaque psoriasis was a serendipitous passenger on the psoriatic arthritis train. Over many years of development, dozens of clinical trials, and thousands of patients in registries, we know TNF to be a central cytokine mediating many chronic inflammatory diseases. We also know that therapeutic blockade of TNF is remarkably safe. Yet to be established are collateral benefits of treatment with TNF antagonists.
Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psor... more Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psoriasis in randomized clinical trials.
Uploads
Papers by Kim Papp